The Future Is Now; Med Tech That’s Changing Lives

March 1, 2019

Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many of these “far off” projects are now on the verge of reality.

According to IDTechEx “The market for bioelectronic medicine will exceed $60 billion by 2029.” They explain Bioelectronic medicine, or electroceuticals, is the use of electrical stimulation to treat diseases of the human body in ways that current pharmaceutical interventions cannot.

BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.

“With the use of the PURE EP™ System, I was able to identify cardiac signals which were previously undetectable to me. I believe that the PURE EP™ System could change diagnostic and treatment strategies of arrhythmias, leading to more successful outcomes,” commented Dr. Andrea Natale, who conducted the studies.

The PURE EP™ System was used during standard studies on patients with persistent atrial fibrillation and conducted in parallel with Abbott’s EnSite Precision™ and Biosense Webster’s (Johnson & Johnson) CARTO™ cardiac mapping systems. The goal of the first commercial use of the technology was aimed at validating the System’s key value proposition elements and report on the overall user experience during the procedure.

Kenneth L. Londoner, Chairman and CEO of BioSig Technologies stated, “We are well positioned to deliver on our strategic goals for 2019 and look forward to the expansion of our evaluation efforts in the coming months.”

The BioSig Technologies system will sell for $250,000 each, in addition to a $100,000 software license.

See the latest posts on our homepage


Share

Topic Area: Press Release


Recent Posts
Recent Posts
Focus: Infection Control

Agencies investigating Legionnaires' case at McLaren Flint


Hospital officials acknowledging that a patient may have acquired the disease at the facility

5/24/2019

Focus: Infection Control

Study: Outside temperature impacts pathogens in climate-controlled ICUs


The outside temperature can influence the indoor temperature

5/24/2019

Security hired for Manitoba healthcare facilities after city bills for police time


Province announces two guards will be on staff at all times

5/24/2019

Blog

When to consolidate clinical testing (core) laboratories.


Increasingly, customers of clinical testing labs want a one-stop shop, particularly as large healthcare systems acquire smaller, more specialized independent practices

5/24/2019

'Best Places to Work' in healthcare named


Modern Healthcare shares alphabetical list of winners

5/24/2019





Post Comment




FREE
NEWSLETTER

News & Updates • Webcast Alerts • Building Technologies

All fields are required.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.